- Home
- PAM vs PRCT Comparison
PAM vs PRCT Comparison
Compare PAM & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAM
- PRCT
- Stock Information
- Founded
- PAM 1945
- PRCT 2009
- Country
- PAM Argentina
- PRCT United States
- Employees
- PAM N/A
- PRCT N/A
- Industry
- PAM Electric Utilities: Central
- PRCT Medical Specialities
- Sector
- PAM Utilities
- PRCT Health Care
- Exchange
- PAM Nasdaq
- PRCT Nasdaq
- Market Cap
- PAM 3.9B
- PRCT 3.2B
- IPO Year
- PAM N/A
- PRCT 2021
- Fundamental
- Price
- PAM $76.63
- PRCT $58.00
- Analyst Decision
- PAM Buy
- PRCT Strong Buy
- Analyst Count
- PAM 4
- PRCT 7
- Target Price
- PAM $75.88
- PRCT $90.00
- AVG Volume (30 Days)
- PAM 200.7K
- PRCT 850.8K
- Earning Date
- PAM 05-12-2025
- PRCT 04-24-2025
- Dividend Yield
- PAM N/A
- PRCT N/A
- EPS Growth
- PAM 32.60
- PRCT N/A
- EPS
- PAM 0.41
- PRCT N/A
- Revenue
- PAM $1,970,436,590.00
- PRCT $249,121,000.00
- Revenue This Year
- PAM $127,194.51
- PRCT $47.40
- Revenue Next Year
- PAM $22.99
- PRCT $31.81
- P/E Ratio
- PAM $7.46
- PRCT N/A
- Revenue Growth
- PAM 21.62
- PRCT 59.36
- 52 Week Low
- PAM $38.58
- PRCT $47.04
- 52 Week High
- PAM $97.55
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- PAM 45.40
- PRCT 54.16
- Support Level
- PAM $78.75
- PRCT $55.18
- Resistance Level
- PAM $82.78
- PRCT $59.06
- Average True Range (ATR)
- PAM 3.74
- PRCT 2.64
- MACD
- PAM -0.48
- PRCT 0.16
- Stochastic Oscillator
- PAM 7.72
- PRCT 78.08
About PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business. The operating business segments of the firm are Electricity generation, Electricity distribution, Oil and Gas, Petrochemicals, and Holding and other business. The company derives the maximum revenue from the Distribution of energy.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.